Lapatinib

Drug Profile

Lapatinib

Alternative Names: 572016; Cipatinib; GSK-572016; GW-2016; GW-572016; GW-572016F; Lapatinib ditosilate; Lapatinib ditosylate; Tycerb; Tykerb; Tyverb

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer Beth Israel Deaconess Medical Center; Eddingpharm; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; GlaxoSmithKline; Novartis
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Furans; Phenyl ethers; Quinazolines; Small molecules; Sulfones
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Brain metastases
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Discontinued Gastric cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from the phase III ALTTO trial in Breast cancer (adjuvant therapy) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
  • 02 Jun 2017 Safety and efficacy data from the phase III ALTERNATIVE trial presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 May 2017 Novartis terminates a phase II trial due to lack of significant signal of efficacy in Brain metastases (Combination therapy) in USA (IV) (NCT01934894)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top